9.98
+15.38%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bicara Therapeutics
From its filings with the US Securities and Exchange Commission
Bicara Therapeutics is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BCAX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $137.9m. At that date it held total assets of $431.0m and shareholders' equity of $401.5m.
We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity. This approach was deployed in the development of our lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-β, ligand trap.
By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the TME. Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will drive the tumor penetration of immune cells that lead to deep and durable responses and an increase in overall survival, or OS.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Sept 2024
- Employees
- 103
- Website
- bicara.com ↗
- Head office
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Michael PowellIndependent Chairman of the Board$456,875
- Dr. Ryan CohlheppPresident, Chief Operating Officer, Director, since 2020$4.5m
- Dr. Claire MazumdarChief Executive Officer, Director, since 2020$8.9m
- Mr. Ivan HyepChief Financial Officer$3.6m
- Dr. David RabenChief Medical Officer
- Ms. Lara MeisnerChief Legal Officer, Corporate Secretary
- Dr. AM Christopher BowdenIndependent Director$439,783
- Ms. Kate HavilandIndependent Director$361,352
- Dr. Nils LonbergIndependent Director$364,749
- Dr. Kiran Mazumdar ShawIndependent Director$332,901
- Dr. Carolyn NgIndependent Director
- Mr. Scott RobertsonIndependent Director$364,341
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bicara Therapeutics' lead program ficerafusp alfa targets head and neck squamous cell carcinoma with dual EGFR and TGF-b mechanisms.
- The company's clinical-stage biotechnology platform focuses on first-in-class biologics for tumor microenvironment modulation.
- Bicara Therapeutics has 103 employees and is listed on 13 September 2024, indicating strong growth potential.
Weaknesses
- Bicara Therapeutics has only 32 full-time employees, which may limit operational capacity.
- The company's IPO on 13 September 2024 is recent, indicating limited market history.
- Ficerafusp alfa is initially developed for head and neck squamous cell carcinoma, a specific segment with high competition.
Opportunities
- The unmet need in head and neck squamous cell carcinoma presents a significant market opportunity for ficerafusp alfa.
- Bicara Therapeutics' platform can facilitate the development of bifunctional therapies for other tumor types.
- The biotechnology sector in the US offers substantial growth potential for clinical-stage companies.
Threats
- Head and neck squamous cell carcinoma has high competition from existing treatments and therapies.
- The recent IPO on 13 September 2024 may face market volatility and investor skepticism.
- The biotechnology industry faces regulatory challenges and high development costs for new therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.